Daclatasvir Dihydrochloride
Also known as: Daklinza, Natdac, Dacihep, Daclahep, Mydekla
CAS Number: 1009119-65-6
Antiviral (HCV NS5A Replication Complex Inhibitor)
Pharmacopeia Standards
Mechanism of Action
Daclatasvir binds domain I of the hepatitis C NS5A protein, a non-enzymatic phosphoprotein essential to assembly of the viral replication complex. Binding disrupts both formation of new replication complexes on the endoplasmic reticulum membrane and the later virion assembly and secretion steps. The dual block on RNA replication and assembly produces very rapid multi-log declines in viral load when combined with a polymerase inhibitor.
Technical Specifications
| Generic / INN Name | Daclatasvir Dihydrochloride |
| CAS Registry Number | 1009119-65-6 |
| Molecular Formula | C40H52Cl2N8O6 |
| Molecular Weight | 811.81 g/mol g/mol |
| Typical Purity | Not less than 98.0% on anhydrous basis calculated as daclatasvir |
| Storage Conditions | Store below 25 degrees C in tightly closed, light-resistant containers with desiccant; highly hygroscopic. |
| Shelf Life | 36 months from date of manufacture in original sealed packing |
| Category | Antivirals |
Specifications are indicative and intended for sourcing reference only. Always confirm against the supplier's Certificate of Analysis and the applicable pharmacopeial monograph before issuing a purchase specification.
Typical Applications
Bulk API for 30 mg and 60 mg film-coated tablets used together with sofosbuvir, and for co-packaged or fixed-dose hepatitis C regimens supplied to national elimination programmes.
Manufacturers (0+)
View all →Do you manufacture Daclatasvir Dihydrochloride? Add your free listing and reach global buyers.
Add listing — FreeCan you supply Daclatasvir Dihydrochloride? List as an authorised distributor or export house.
Register as traderEarn commission by connecting buyers with verified API suppliers. Free to join.
Become an agent